Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 2000 |
No grāmatas satura
6.–10. rezultāts no 46.
16. lappuse
... bear the warning statement " This product contains FD & C Yellow No. 5 ( tartrazine ) which may cause allergic - type reactions ( in- cluding bronchial asthma ) in certain susceptible persons . Although the over- all incidence of FD & C ...
... bear the warning statement " This product contains FD & C Yellow No. 5 ( tartrazine ) which may cause allergic - type reactions ( in- cluding bronchial asthma ) in certain susceptible persons . Although the over- all incidence of FD & C ...
17. lappuse
... bear the warning specified in paragraph ( b ) or ( c ) of this section . ( b ) The labeling required by §§ 201.57 and 201.100 ( d ) for prescription drugs for human use containing a sulfite , except epinephrine for injection when in ...
... bear the warning specified in paragraph ( b ) or ( c ) of this section . ( b ) The labeling required by §§ 201.57 and 201.100 ( d ) for prescription drugs for human use containing a sulfite , except epinephrine for injection when in ...
18. lappuse
... bear as one of its principal fea- tures a statement of the identity of the drug . ( b ) Such statement of identity shall be in terms of the established name of the drug . In the case of a prescriptio drug that is a mixture and that has ...
... bear as one of its principal fea- tures a statement of the identity of the drug . ( b ) Such statement of identity shall be in terms of the established name of the drug . In the case of a prescriptio drug that is a mixture and that has ...
19. lappuse
... bear a state- ment of the recommended or usual dos- age . Since the dosage for some pre- scription drugs varies within extremely wide limits , depending upon the condi- tions being treated , it may not be pos- sible in all cases to ...
... bear a state- ment of the recommended or usual dos- age . Since the dosage for some pre- scription drugs varies within extremely wide limits , depending upon the condi- tions being treated , it may not be pos- sible in all cases to ...
23. lappuse
... bear the statement required under the cat- egory : ( a ) Pregnancy category A. If adequate and well - controlled studies in pregnant women have failed to demonstrate a risk to the fetus in the first trimester of pregnancy ( and there is ...
... bear the statement required under the cat- egory : ( a ) Pregnancy category A. If adequate and well - controlled studies in pregnant women have failed to demonstrate a risk to the fetus in the first trimester of pregnancy ( and there is ...
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
active ingredient adequate administered or dispensed advertisement amended appropriate approved Authority citation revised batch beling chapter clinical Code components Cosmetic Act Department detoxification distribution dosage form dose Drug Administration drug application Drug Establishment Drug Facts drug listing drug prod drug products containing drug sample effective equipment established name evaluation exemption Federal Acquisition Regulation Federal Food Federal Register Food and Drug hexachlorophene human labeling licensed practitioner manufac manufacturer manufacturing practice medicated article(s medicated feed Medication Guide ment methadone milligrams misbranded narcotic drugs National National Drug Code Office oral OTC drug products over-the-counter drug package Packaging and labeling paragraph patient patient's record pediatric person Pregnancy Category pregnant prescription drug procedures program physician proprietary name quantity quired request responsible Service sodium specific submitted taining take-home medication tamper-evident tients tion treatment plan treatment program Type A medicated unit
Populāri fragmenti
18. lappuse - There are. however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed...
10. lappuse - USP) 2.5, 5, and 10 mg contain FD&C Yellow No. 5 (tartrazine) which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of FD&C Yellow No. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.
18. lappuse - ProHance* should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
19. lappuse - Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Lortab 7.5/500 tablets, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
45. lappuse - Labeling on or within the package from which the drug is to be dispensed bears adequate information for its use, including indications, effects, dosages, routes, methods, and frequency and duration of administration, and any relevant hazards, contraindications, side effects, and precautions...
19. lappuse - Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when sucralfate is administered to a nursing woman.
58. lappuse - The same information concerning the ingredients of the drug as appears on the label and labeling on or within the package from which the drug is to be dispensed...
173. lappuse - Office of the Assistant Secretary for Housing — Federal Housing Commissioner, Department of Housing and Urban Development (Section 8 Housing Assistance Programs, Section 202 Direct Loan Program, Section 202 Supportive Housing for the Elderly Program and Section 811 Supportive Housing for Persons With Disabilities Program) (Parts 800—899) IX Office of Assistant Secretary for Public and Indian Housing, Department of Housing and Urban Development (Parts 900—999...
48. lappuse - Act (1) small open containers of fresh fruits and fresh vegetables and (2) food which is, in accordance with the practice of the trade, to be processed, labeled, or repacked in substantial quantities at establishments other than those where originally processed or packed, on condition that such food is not adulterated or misbranded under the provisions of this Act upon removal from such processing, labeling, or repacking establishment.
173. lappuse - Bureau of Land Management, Department of the Interior (Parts 1000—9999) III Utah Reclamation Mitigation and Conservation Commission (Parts...